Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 10 2019
Historique:
received: 19 07 2019
accepted: 02 10 2019
entrez: 20 10 2019
pubmed: 20 10 2019
medline: 15 12 2020
Statut: epublish

Résumé

The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor agonism, are currently unavailable. Here, we investigated [

Identifiants

pubmed: 31628379
doi: 10.1038/s41598-019-51530-0
pii: 10.1038/s41598-019-51530-0
pmc: PMC6800434
doi:

Substances chimiques

Biomarkers 0
Glucagon-Like Peptide-1 Receptor 0
Ligands 0
Peptides 0
Receptors, Glucagon 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14960

Références

Endocrinology. 2018 Aug 1;159(8):3105-3119
pubmed: 29992313
J Nucl Med. 2007 Apr;48(4):596-601
pubmed: 17401097
J Nucl Med. 2013 Aug;54(8):1458-63
pubmed: 23761918
Diabetes. 2009 Oct;58(10):2258-66
pubmed: 19602537
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
J Med Chem. 2017 May 25;60(10):4293-4303
pubmed: 28448133
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1800-10
pubmed: 24643781
Nat Chem Biol. 2009 Oct;5(10):749-57
pubmed: 19597507
Diabetologia. 2017 Oct;60(10):1851-1861
pubmed: 28733905
EJNMMI Res. 2019 Feb 15;9(1):17
pubmed: 30771019

Auteurs

Olof Eriksson (O)

Antaros Medical AB, Mölndal, Sweden. olof.eriksson@antarosmedical.com.
Science For Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden. olof.eriksson@antarosmedical.com.

Irina Velikyan (I)

PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, Sweden.
Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

Torsten Haack (T)

Sanofi-Aventis, Frankfurt, Germany.

Martin Bossart (M)

Sanofi-Aventis, Frankfurt, Germany.

Andreas Evers (A)

Sanofi-Aventis, Frankfurt, Germany.

Iina Laitinen (I)

Sanofi-Aventis, Frankfurt, Germany.

Philip J Larsen (PJ)

Sanofi-Aventis, Frankfurt, Germany.
Bayer Pharmaceuticals, Wuppertal, Germany.

Oliver Plettenburg (O)

Sanofi-Aventis, Frankfurt, Germany.
Institute of Medicinal Chemistry, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
Institute of Organic Chemistry, Leibniz Universität Hannover, Hannover, Germany.

Akihiro Takano (A)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Christer Halldin (C)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

Gunnar Antoni (G)

PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, Sweden.
Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

Lars Johansson (L)

Antaros Medical AB, Mölndal, Sweden.

Stefan Pierrou (S)

Antaros Medical AB, Mölndal, Sweden.

Michael Wagner (M)

Sanofi-Aventis, Frankfurt, Germany. michael.wagner@sanofi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH